DuraGraft
DuraGraft® is a one time intraoperative vascular graft treatment that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure thereby improving clinical outcomes.
Intraoperative Graft Damage is the principal cause of vein graft disease
The durability and patency of vein grafts are significantly compromised by Vein Graft Disease (VGD):
- The VGD process begins during the grafting surgery itself
- VGD is the principal cause of both early (within 30 days) and intermediate/late Vein Graft Failure (VGF)
- VGD encompasses the pathophysiological changes that occur in vein grafts following their use in surgical grafting
DuraGraft® Treatment Improves Clinical Outcomes
DuraGraft Clinical Study Summary
U.S. Retrospective Study • 2436 CABG Patients • DuraGraft Treatment vs. No Treatment
Unadjusted Analysis: 43 % ( p =<0.0001)
IPW Adjusted: 45 % ( p =<0.0001)
Reduction in Myocardial Infarction Rates
Unadjusted Analysis: 31 % ( p =0.002)
IPW Adjusted: 35 % ( p =0.037)
Reduction in Repeat Revascularization Rates
Unadjusted Analysis: 21 % ( p =<0.0001)
IPW Adjusted: 19 % ( p =0.005)
Reduction in MACE Rates
DuraGraft Pilot Study
EU Retrospective Study • Five-year Study • 630 CABG Patients • DuraGraft Treatment vs. No Treatment
70% Reduction
Myocardial Infarction Rates
57% Reduction
Repeat Revascularization Rates
23% Reduction
All Cause Death Rates
37% Reduction
MACE Rates
Endothelial Damage, Manifested Within Minutes as Pro-inflammatory, Pro-thrombogenic, and Hyper-proliferative Changes Within the Graft, Leads to VGD
Intraoperative Graft Damage is the Principal Cause of Vein Graft Failure
As VGD progresses, vein grafts lose their ability to adapt to the post-grafting environment, leading to :
- Thrombus formation
- Intimal hyperplasia
- Atherosclerosis
These may result in :
- Graft stenosis
- Occlusion
- Loss of graft patency
